ABSTRACT
A 49-year-old female suffered from increasing dyspnea from 2004. She had undergone mitral valve replacement with Carpentier-Edwards 1st-generation standard porcine bioprosthesis due to mitral stenosis 22-years ago. The echocardiography and catheterization showed mitral stenosis and, regurgitation. Re-replacement of the mitral prosthetic valve with ATS (27 mm) valve and tricuspid annuloplasty with Edwards MC3 Ring were successfully performed. There was no case who underwent so long post operative period after initial implantation of fragile prosthetic valve.
Subject(s)
Bioprosthesis , Heart Valve Prosthesis Implantation , Heart Valve Prosthesis , Mitral Valve Stenosis/surgery , Animals , Female , Humans , Middle Aged , Mitral Valve Insufficiency/surgery , Prosthesis Failure , Reoperation , Swine , Time Factors , Treatment OutcomeABSTRACT
In 1984, the patient, a 68-year-old male, underwent pacemaker implantation for the treatment of sick sinus syndrome. Because of a postoperative pocket infection, the atrial lead was removed ; but it was difficult to extract the ventricular lead, which was therefore left in place. While under observation, transient facial edema, atrial fibrillation, chest discomfort were noted. Chest X-ray revealed that the ventricular lead had gradually moved to the side of the pulmonary artery. Pre-operative phlebography of the internal jugular vein led to a diagnosis of obstruction of the superior vena cava (SVC). Maze procedure was performed and the lead was readily removed through the right atriotomy. The obstruction was incised and the lesion reconstructed by using a patch by the autologous pericardium. The satisfactory return of circulation was confirmed by postoperative imaging. At the discharge, an electrocardiograph indicated a sinus rhythm and a heart rate was 82 ppm. The facial edema and thoracic symptoms had been completely eliminated.
Subject(s)
Angioplasty , Atrial Fibrillation/therapy , Cardiac Surgical Procedures/methods , Pacemaker, Artificial , Superior Vena Cava Syndrome/surgery , Aged , Chronic Disease , Humans , Male , Pericardium/transplantation , Postoperative Complications , Sick Sinus Syndrome/surgery , Superior Vena Cava Syndrome/etiology , Transplantation, AutologousABSTRACT
We investigated the anti-ulcer effects of zinc L-carnosine (Z-103) using several acute experimental models of gastric and duodenal lesions in rats. Effects of Z-103 on various gastric functions, e.g., antacid (in vitro), anti-pepsin (in vitro), gastric secretion, mucosal potential difference (PD) and mucus contents were also examined. Z-103 given orally prevented development of gastric lesions induced by water immersion stress, histamine, HCl-aspirin, HCl-ethanol and also duodenal ulcers induced by mepirizole in a dose-dependent manner. In vitro, Z-103 had a greater antacid effect than sodium bicarbonate; and moreover, the potency of its anti-peptic action (IC50 = 8.7 mM) was higher than those of several other drugs (sodium bicarbonate, sucrose sulfate and aceglutamide aluminum). Intragastric treatment of Z-103 (100 mg/kg alone tended to increase PD, and it also significantly inhibited the decrease in PD induced by aspirin. In addition, pretreatment with Z-103 at 10 and 30 mg/kg (p.o.) significantly prevented the decrease in mucus contents in the gastric mucosa and also mucosal lesions by oral administration of ethanol. On the other hand, Z-103 was not so effective on both basal (pylorus-ligation preparation) and histamine-stimulated gastric secretion (Heidenhain pouch preparation). These results suggest that Z-103 is useful for the treatment of gastric and duodenal ulcers in humans.
